CA2287084A1 - Diagnosis method and reagents - Google Patents

Diagnosis method and reagents Download PDF

Info

Publication number: CA2287084A1
Authority: CA; Canada
Prior art keywords: seq; disease; protein; mutant; rna
Prior art date: 1997-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002287084A

Other languages

English (en)

French (fr)

Inventor

Frederik W. Van Leeuwen

Franklin G. Grosveld

Johannes Peter Henri Burbach

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Erasmus Universiteit Rotterdam

Rijksuniversiteit Utrecht

Koninklijke Nederlandse Akademie van Wetenschappen

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-10

Filing date

1998-04-02

Publication date

1998-10-15

1998-04-02 Application filed by Individual filed Critical Individual

1998-10-15 Publication of CA2287084A1 publication Critical patent/CA2287084A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 111
238000003745 diagnosis Methods 0.000 title claims abstract description 25
239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 16
108090000623 proteins and genes Proteins 0.000 claims abstract description 252
102000004169 proteins and genes Human genes 0.000 claims abstract description 176
201000010099 disease Diseases 0.000 claims abstract description 174
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 174
230000037433 frameshift Effects 0.000 claims abstract description 128
230000035772 mutation Effects 0.000 claims abstract description 125
231100000221 frame shift mutation induction Toxicity 0.000 claims abstract description 100
238000011282 treatment Methods 0.000 claims abstract description 34
210000001124 body fluid Anatomy 0.000 claims abstract description 16
239000010839 body fluid Substances 0.000 claims abstract description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 207
210000004027 cell Anatomy 0.000 claims description 193
108010021466 Mutant Proteins Proteins 0.000 claims description 92
102000008300 Mutant Proteins Human genes 0.000 claims description 92
102000053642 Catalytic RNA Human genes 0.000 claims description 74
108090000994 Catalytic RNA Proteins 0.000 claims description 74
108091092562 ribozyme Proteins 0.000 claims description 74
208000024827 Alzheimer disease Diseases 0.000 claims description 68
101100228149 Drosophila melanogaster Trl gene Proteins 0.000 claims description 66
241001123946 Gaga Species 0.000 claims description 66
239000002773 nucleotide Substances 0.000 claims description 66
125000003729 nucleotide group Chemical group 0.000 claims description 65
239000013598 vector Substances 0.000 claims description 62
150000007523 nucleic acids Chemical class 0.000 claims description 60
239000000523 sample Substances 0.000 claims description 57
102000039446 nucleic acids Human genes 0.000 claims description 50
108020004707 nucleic acids Proteins 0.000 claims description 50
238000012217 deletion Methods 0.000 claims description 45
230000037430 deletion Effects 0.000 claims description 44
230000000295 complement effect Effects 0.000 claims description 39
210000001519 tissue Anatomy 0.000 claims description 39
108020004414 DNA Proteins 0.000 claims description 33
125000003275 alpha amino acid group Chemical group 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 32
206010012289 Dementia Diseases 0.000 claims description 26
-1 Big Tau Proteins 0.000 claims description 24
238000001514 detection method Methods 0.000 claims description 23
102000015499 Presenilins Human genes 0.000 claims description 22
108010050254 Presenilins Proteins 0.000 claims description 22
208000015122 neurodegenerative disease Diseases 0.000 claims description 22
239000012634 fragment Substances 0.000 claims description 21
108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
239000012472 biological sample Substances 0.000 claims description 18
230000004770 neurodegeneration Effects 0.000 claims description 18
102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 17
101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 15
101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 15
210000000349 chromosome Anatomy 0.000 claims description 15
108010026424 tau Proteins Proteins 0.000 claims description 15
108010060159 Apolipoprotein E4 Proteins 0.000 claims description 14
102000044159 Ubiquitin Human genes 0.000 claims description 14
108090000848 Ubiquitin Proteins 0.000 claims description 14
102000013498 tau Proteins Human genes 0.000 claims description 14
102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 13
108010088373 Neurofilament Proteins Proteins 0.000 claims description 13
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 13
230000015572 biosynthetic process Effects 0.000 claims description 13
238000003780 insertion Methods 0.000 claims description 13
230000037431 insertion Effects 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
230000002441 reversible effect Effects 0.000 claims description 13
238000002560 therapeutic procedure Methods 0.000 claims description 13
101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims description 12
102000008763 Neurofilament Proteins Human genes 0.000 claims description 12
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 12
101150080074 TP53 gene Proteins 0.000 claims description 12
238000006243 chemical reaction Methods 0.000 claims description 12
239000002853 nucleic acid probe Substances 0.000 claims description 12
101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 11
210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 11
208000011580 syndromic disease Diseases 0.000 claims description 11
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
108091012583 BCL2 Proteins 0.000 claims description 9
102100027974 Semaphorin-3A Human genes 0.000 claims description 9
108010090319 Semaphorin-3A Proteins 0.000 claims description 9
206010012601 diabetes mellitus Diseases 0.000 claims description 9
238000009007 Diagnostic Kit Methods 0.000 claims description 8
208000018737 Parkinson disease Diseases 0.000 claims description 8
208000027089 Parkinsonian disease Diseases 0.000 claims description 8
206010034010 Parkinsonism Diseases 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
239000003550 marker Substances 0.000 claims description 8
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
230000002163 immunogen Effects 0.000 claims description 7
201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
102100023174 Methionine aminopeptidase 2 Human genes 0.000 claims description 6
108090000192 Methionyl aminopeptidases Proteins 0.000 claims description 6
102000009664 Microtubule-Associated Proteins Human genes 0.000 claims description 6
108010020004 Microtubule-Associated Proteins Proteins 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
239000005022 packaging material Substances 0.000 claims description 6
230000008506 pathogenesis Effects 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 5
238000012163 sequencing technique Methods 0.000 claims description 5
208000022309 Alcoholic Liver disease Diseases 0.000 claims description 4
208000011403 Alexander disease Diseases 0.000 claims description 4
208000011990 Corticobasal Degeneration Diseases 0.000 claims description 4
206010011659 Cutaneous amyloidosis Diseases 0.000 claims description 4
206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
201000002832 Lewy body dementia Diseases 0.000 claims description 4
208000001089 Multiple system atrophy Diseases 0.000 claims description 4
206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 4
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
230000002308 calcification Effects 0.000 claims description 4
210000000981 epithelium Anatomy 0.000 claims description 4
210000001652 frontal lobe Anatomy 0.000 claims description 4
210000004276 hyalin Anatomy 0.000 claims description 4
210000003000 inclusion body Anatomy 0.000 claims description 4
230000003902 lesion Effects 0.000 claims description 4
208000015413 lichen amyloidosis Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 4
230000037432 silent mutation Effects 0.000 claims description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 3
208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 3
208000017004 dementia pugilistica Diseases 0.000 claims description 3
238000003757 reverse transcription PCR Methods 0.000 claims 3
102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 35
230000001225 therapeutic effect Effects 0.000 abstract description 14
238000002405 diagnostic procedure Methods 0.000 abstract description 7
108090000765 processed proteins & peptides Proteins 0.000 description 39
239000002502 liposome Substances 0.000 description 37
239000000463 material Substances 0.000 description 30
239000000047 product Substances 0.000 description 24
238000003776 cleavage reaction Methods 0.000 description 23
108020004999 messenger RNA Proteins 0.000 description 23
230000007017 scission Effects 0.000 description 22
102000004196 processed proteins & peptides Human genes 0.000 description 21
241001465754 Metazoa Species 0.000 description 17
210000004556 brain Anatomy 0.000 description 17
230000014509 gene expression Effects 0.000 description 17
230000000875 corresponding effect Effects 0.000 description 16
239000011159 matrix material Substances 0.000 description 16
101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
229940088598 enzyme Drugs 0.000 description 13
210000002569 neuron Anatomy 0.000 description 13
241000700159 Rattus Species 0.000 description 12
239000012528 membrane Substances 0.000 description 12
210000004379 membrane Anatomy 0.000 description 12
108091026890 Coding region Proteins 0.000 description 11
108020004705 Codon Proteins 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 11
102100030432 Polyubiquitin-B Human genes 0.000 description 11
108010004977 Vasopressins Proteins 0.000 description 11
102000002852 Vasopressins Human genes 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
230000009261 transgenic effect Effects 0.000 description 11
102000014914 Carrier Proteins Human genes 0.000 description 10
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
108091008324 binding proteins Proteins 0.000 description 10
230000001537 neural effect Effects 0.000 description 10
150000003904 phospholipids Chemical class 0.000 description 10
238000010186 staining Methods 0.000 description 10
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 9
238000003556 assay Methods 0.000 description 9
230000027455 binding Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000005538 encapsulation Methods 0.000 description 9
210000003958 hematopoietic stem cell Anatomy 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
238000012360 testing method Methods 0.000 description 9
229960003726 vasopressin Drugs 0.000 description 9
241000124008 Mammalia Species 0.000 description 8
108700019146 Transgenes Proteins 0.000 description 8
239000007788 liquid Substances 0.000 description 8
210000002682 neurofibrillary tangle Anatomy 0.000 description 8
238000001890 transfection Methods 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
208000037259 Amyloid Plaque Diseases 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
230000032683 aging Effects 0.000 description 7
230000003321 amplification Effects 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000000527 sonication Methods 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
108060003951 Immunoglobulin Proteins 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
210000001185 bone marrow Anatomy 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000008859 change Effects 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000002596 correlated effect Effects 0.000 description 6
210000005153 frontal cortex Anatomy 0.000 description 6
230000006870 function Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000001415 gene therapy Methods 0.000 description 6
210000001320 hippocampus Anatomy 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
239000000017 hydrogel Substances 0.000 description 6
102000018358 immunoglobulin Human genes 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002372 labelling Methods 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
108700028369 Alleles Proteins 0.000 description 5
108020005544 Antisense RNA Proteins 0.000 description 5
101150034518 Iapp gene Proteins 0.000 description 5
241000251131 Sphyrna Species 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
239000003184 complementary RNA Substances 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
210000005044 neurofilament Anatomy 0.000 description 5
239000002243 precursor Substances 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
230000001177 retroviral effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
238000012546 transfer Methods 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
108091028664 Ribonucleotide Proteins 0.000 description 4
239000012722 SDS sample buffer Substances 0.000 description 4
101150037646 VP gene Proteins 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 4
230000008499 blood brain barrier function Effects 0.000 description 4
210000001218 blood-brain barrier Anatomy 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000008105 immune reaction Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
210000004153 islets of langerhan Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
210000002511 neuropil thread Anatomy 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000002336 ribonucleotide Substances 0.000 description 4
125000002652 ribonucleotide group Chemical group 0.000 description 4
238000007789 sealing Methods 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000002123 temporal effect Effects 0.000 description 4
238000013519 translation Methods 0.000 description 4
238000001262 western blot Methods 0.000 description 4
208000002109 Argyria Diseases 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
230000001594 aberrant effect Effects 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000002306 biochemical method Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
210000003710 cerebral cortex Anatomy 0.000 description 3
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
238000012937 correction Methods 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000001125 extrusion Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000002241 neurite Anatomy 0.000 description 3
108010091047 neurofilament protein H Proteins 0.000 description 3
230000035699 permeability Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000000758 substrate Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
239000011800 void material Substances 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
206010069754 Acquired gene mutation Diseases 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
101710104359 F protein Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
CTVJSFRHUOSCQQ-DCAQKATOSA-N Met-Arg-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CTVJSFRHUOSCQQ-DCAQKATOSA-N 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
238000010240 RT-PCR analysis Methods 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
102000007238 Transferrin Receptors Human genes 0.000 description 2
108010033576 Transferrin Receptors Proteins 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000002788 anti-peptide Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000000039 congener Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
210000004700 fetal blood Anatomy 0.000 description 2
239000000835 fiber Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
238000010448 genetic screening Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000000777 hematopoietic system Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000000869 mutational effect Effects 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
239000004810 polytetrafluoroethylene Substances 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000009877 rendering Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000037439 somatic mutation Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
230000008016 vaporization Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
102100033639 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
208000006888 Agnosia Diseases 0.000 description 1
241001047040 Agnosia Species 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
206010003062 Apraxia Diseases 0.000 description 1
101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
101100460146 Arabidopsis thaliana NEET gene Proteins 0.000 description 1
QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000004736 B-Cell Leukemia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
108010053652 Butyrylcholinesterase Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
101100471685 Caenorhabditis elegans ubq-2 gene Proteins 0.000 description 1
101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
102100032404 Cholinesterase Human genes 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
238000012287 DNA Binding Assay Methods 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
208000031124 Dementia Alzheimer type Diseases 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
229920002148 Gellan gum Polymers 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
241000630665 Hada Species 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101100434309 Homo sapiens ADA gene Proteins 0.000 description 1
101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
101100462513 Homo sapiens TP53 gene Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033864 Paranoia Diseases 0.000 description 1
208000027099 Paranoid disease Diseases 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102000014105 Semaphorin Human genes 0.000 description 1
108050003978 Semaphorin Proteins 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
101150005400 Sobp gene Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
108010088160 Staphylococcal Protein A Proteins 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
102100033504 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000037280 Trisomy Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
OGFYGJDCQZJOFN-UHFFFAOYSA-N [O].[Si].[Si] Chemical compound [O].[Si].[Si] OGFYGJDCQZJOFN-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
DAPUDVOJPZKTSI-UHFFFAOYSA-L ammonium nickel sulfate Chemical compound [NH4+].[NH4+].[Ni+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DAPUDVOJPZKTSI-UHFFFAOYSA-L 0.000 description 1
229940062331 androgel Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
230000003140 astrocytic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
108700041737 bcl-2 Genes Proteins 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000004781 brain capillary Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229920003174 cellulose-based polymer Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940041694 estrogel Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000028023 exocytosis Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000000216 gellan gum Substances 0.000 description 1
235000010492 gellan gum Nutrition 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000046587 human MAP2 Human genes 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006028 immune-suppresssive effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000012760 immunocytochemical staining Methods 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000012309 immunohistochemistry technique Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000003933 intellectual function Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000009593 lumbar puncture Methods 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
238000007403 mPCR Methods 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
230000007659 motor function Effects 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
210000000478 neocortex Anatomy 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229960002378 oftasceine Drugs 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000009163 protein therapy Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000031539 regulation of cell division Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000005222 synovial tissue Anatomy 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000007332 vesicle formation Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Psychology (AREA)
General Physics & Mathematics (AREA)
Obesity (AREA)

CA002287084A 1997-04-10 1998-04-02 Diagnosis method and reagents Abandoned CA2287084A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4316397P	1997-04-10	1997-04-10
US60/043,163		1997-04-10
PCT/IB1998/000705 WO1998045322A2 (en)	1997-04-10	1998-04-02	Diagnosis method and reagents

Publications (1)

Publication Number	Publication Date
CA2287084A1 true CA2287084A1 (en)	1998-10-15

Family

ID=21925819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002287084A Abandoned CA2287084A1 (en)	1997-04-10	1998-04-02	Diagnosis method and reagents

Country Status (5)

Country	Link
EP (1)	EP0971952A2 (ja)
JP (1)	JP2001522241A (ja)
AU (1)	AU7071598A (ja)
CA (1)	CA2287084A1 (ja)
WO (1)	WO1998045322A2 (ja)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO314086B1 (no)	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
AU2715601A (en) *	1999-12-03	2001-06-12	Koninklijke Nederlandse Akademie Van Wetenschappen	Clearance of aberrant protein in correlation with disease
WO2003008970A1 (fr) *	2001-07-19	2003-01-30	Sysmex Corporation	Procede de detection de ps2v
WO2004001421A2 (en) *	2002-06-21	2003-12-31	Innogenetics N.V.	Method for the diagnosis and differential diagnosis of neurological diseases
JP5116937B2 (ja)	2003-09-16	2013-01-09	独立行政法人国立がん研究センター	哺乳動物由来の検体の癌化度を評価する方法
CA2547165C (en)	2003-11-25	2014-07-08	Ira H. Pastan	Mutated anti-cd22 antibodies and immunoconjugates
FR2869909B1 (fr) *	2004-05-04	2007-12-21	Univ Angers	Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP1916259A1 (en)	2006-10-26	2008-04-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
DK2238170T3 (en)	2008-01-31	2017-02-27	Inserm - Inst Nat De La Santé Et De La Rech Médicale	ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
US8481033B2 (en)	2008-10-07	2013-07-09	INSERM (Institute National de la Santé et de la Recherche Médicale)	Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
WO2010106051A1 (en)	2009-03-17	2010-09-23	Universite De La Mediterranee	Btla antibodies and uses thereof
WO2010128265A2 (fr)	2009-05-07	2010-11-11	Stallergenes S.A.	Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
JP2009203240A (ja) *	2009-06-15	2009-09-10	National Institute Of Advanced Industrial & Technology	リポソームおよびそれからなる細胞への物質導入担体
JP5795765B2 (ja)	2009-09-11	2015-10-14	アメリカ合衆国	低減した免疫原性を有する改良型シュードモナス（Ｐｓｅｕｄｏｍｏｎａｓ）外毒素Ａ
WO2011080322A1 (en)	2009-12-30	2011-07-07	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
US9040671B2 (en)	2010-07-23	2015-05-26	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for cancer management targeting Co-029
EP2412724A1 (en)	2010-07-29	2012-02-01	Centre National de la Recherche Scientifique (C.N.R.S)	Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
WO2012080769A1 (en)	2010-12-15	2012-06-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-cd277 antibodies and uses thereof
EP2654789B1 (en)	2010-12-22	2018-05-30	Orega Biotech	Antibodies against human cd39 and use thereof
WO2012101125A1 (en)	2011-01-24	2012-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Specific antibodies against human cxcl4 and uses thereof
EP2681239B8 (en)	2011-02-28	2015-09-09	F. Hoffmann-La Roche AG	Antigen binding proteins
EP3147297B1 (en)	2011-03-31	2018-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies directed against icos and uses thereof
BR112013028537A2 (pt)	2011-05-06	2017-01-17	Us Gov Health & Human Serv	imunotoxina recombinante que visa a mesotelina
CN103890010B (zh)	2011-05-19	2017-04-19	法国国家健康医学研究院	抗‑人‑her3抗体及其用途
RU2627216C2 (ru)	2011-06-09	2017-08-03	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Экзотоксин а pseudomonas с менее иммуногенными т-и/или в-клеточными эпитопами
ES2677367T3 (es)	2011-06-22	2018-08-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticuerpos anti-Axl y usos de los mismos
CA2839508A1 (en)	2011-06-22	2012-12-27	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-axl antibodies and uses thereof
ES2636679T3 (es)	2011-06-27	2017-10-06	Université Pierre Et Marie Curie (Paris 6)	Péptidos antagonistas de CCR2
EP2543678A1 (en)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the treatment and prevention of thrombosis
PL2755993T3 (pl)	2011-09-16	2018-04-30	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Egzotoksyna A Pseudomonas z mniej immunogennymi epitopami komórek B
US9676847B2 (en)	2012-06-25	2017-06-13	Orega Biotech	IL-17 antagonist antibodies
US9695247B2 (en)	2012-09-03	2017-07-04	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies directed against ICOS for treating graft-versus-host disease
AU2013204200B2 (en)	2012-10-11	2016-10-20	Brandeis University	Treatment of amyotrophic lateral sclerosis
DK2922875T3 (en)	2012-11-20	2017-06-06	Sanofi Sa	ANTI-CEACAM5 ANTIBODIES AND APPLICATIONS THEREOF
JP6441232B2 (ja)	2012-12-27	2018-12-19	サノフイＳａｎｏｆｉ	抗ｌａｍｐ１抗体および抗体薬物コンジュゲート、ならびにその使用
US10005839B2 (en)	2013-05-17	2018-06-26	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antagonist of the BTLA/HVEM interaction for use in therapy
WO2014205187A1 (en)	2013-06-20	2014-12-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
CA2926215A1 (en)	2013-10-06	2015-04-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modified pseudomonas exotoxin a
RU2704228C2 (ru)	2013-11-07	2019-10-24	Инсерм (Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль)	Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения
ES2924393T3 (es)	2014-04-16	2022-10-06	Inst Nat Sante Rech Med	Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
FR3021970B1 (fr)	2014-06-06	2018-01-26	Universite Sciences Technologies Lille	Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MX2017009535A (es)	2015-01-23	2017-11-02	Sanofi Sa	Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
WO2016128349A1 (en)	2015-02-09	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
EP3280455A1 (en)	2015-04-07	2018-02-14	INSERM - Institut National de la Santé et de la Recherche Médicale	Non-invasive imaging of tumor pd-l1 expression
EP3319990A1 (en)	2015-07-07	2018-05-16	Institut National de la Sante et de la Recherche Medicale (INSERM)	Antibodies having specificity to myosin 18a and uses thereof
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
JP2019513008A (ja)	2016-02-26	2019-05-23	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｂｔｌａに対して特異性を有する抗体及びその使用
HUE060189T2 (hu) *	2016-03-18	2023-02-28	Genclis	Allergia molekuláris eredete
EP3468587A4 (en)	2016-06-09	2020-02-19	University of Leicester	MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHOD FOR DETECTING MUCIN-LIKE PROTEIN (MLP) AS A BIOMARKER FOR OVARIAL AND PANCREASER
BR112019001693A2 (pt)	2016-07-29	2019-07-02	Ct Hospitalier Universitaire Toulouse	anticorpos direcionados a macrófagos associados a tumores e seus usos
US11286295B2 (en)	2016-10-20	2022-03-29	Sanofi	Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
KR101885007B1 (ko) *	2016-12-22	2018-08-31	가천대학교 산학협력단	인지기능장애의 진단 방법 및 키트
JP2020510432A (ja)	2017-03-02	2020-04-09	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｎｅｃｔｉｎ−４への特異性を有する抗体及びその使用
CA3051640A1 (en)	2017-03-16	2018-09-20	Innate Pharma	Compositions and methods for treating cancer
EP3658581A1 (en)	2017-07-24	2020-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies and peptides to treat hcmv related diseases
JP7226833B2 (ja)	2017-09-21	2023-02-21	イムチェックセラピューティクスエスエーエス	Ｂｔｎ２に特異性を有する抗体及びその使用
WO2019238686A1 (en) *	2018-06-13	2019-12-19	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A.	Peptides having inhibitory activity on muscarinic receptor m3
WO2019243252A1 (en)	2018-06-18	2019-12-26	Innate Pharma	Compositions and methods for treating cancer
US20210238244A1 (en) *	2018-07-26	2021-08-05	Frame Pharmaceuticals B.V.	Off-the-shelf cancer vaccines
WO2020053122A1 (en)	2018-09-10	2020-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination of her2/neu antibody with heme for treating cancer
EP3941940A1 (en)	2019-03-20	2022-01-26	Imcheck Therapeutics SAS	Antibodies having specificity for btn2 and uses thereof
EP3947446A1 (en)	2019-03-25	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Treatment of taupathy disorders by targeting new tau species
EP4007775A1 (en)	2019-08-02	2022-06-08	Orega Biotech	Novel il-17b antibodies
EP4034560A1 (en)	2019-09-27	2022-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021058729A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021116119A1 (en)	2019-12-09	2021-06-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to her4 and uses thereof
WO2021175954A1 (en)	2020-03-04	2021-09-10	Imcheck Therapeutics Sas	Antibodies having specificity for btnl8 and uses thereof
CA3180872A1 (en)	2020-04-24	2021-10-28	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
IL297311A (en)	2020-04-24	2022-12-01	Sanofi Sa	Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox
KR20230005258A (ko)	2020-04-24	2023-01-09	사노피	항-ceacam5 항체 접합체 및 트리플루리딘 및 티피라실을 함유하는 항종양 병용물
US20230087871A1 (en)	2020-04-24	2023-03-23	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
EP4149558A1 (en)	2020-05-12	2023-03-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
AU2021328262A1 (en)	2020-08-18	2023-03-16	Omeros Corporation	Monoclonal antibodies, compositions and methods for detecting complement factor D
JP2023540732A (ja)	2020-09-04	2023-09-26	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	抗ｃｅａｃａｍ５抗体及びコンジュゲート並びにそれらの使用
CA3208974A1 (en)	2021-01-20	2022-07-28	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
IL310437A (en)	2021-07-29	2024-03-01	Inst Nat Sante Rech Med	Humanized anti-human βig-h3 protein and uses thereof
CA3237142A1 (en)	2021-11-05	2023-05-11	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
WO2023150181A1 (en)	2022-02-01	2023-08-10	President And Fellows Of Harvard College	Methods and compositions for treating cancer
WO2023170239A1 (en)	2022-03-09	2023-09-14	Merck Patent Gmbh	Methods and tools for conjugation to antibodies
KR20240155334A (ko)	2022-03-09	2024-10-28	메르크 파텐트 게엠베하	항-gd2 항체, 면역접합체 및 그의 치료적 용도
WO2023240287A1 (en)	2022-06-10	2023-12-14	Bioentre Llc	Combinations of ctla4 binding proteins and methods of treating cancer
WO2024052503A1 (en)	2022-09-08	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en)	2022-09-12	2024-03-21	Institut National de la Santé et de la Recherche Médicale	New anti-itgb8 antibodies and its uses thereof
WO2024180192A1 (en)	2023-03-01	2024-09-06	Sanofi	Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en)	2023-03-06	2024-09-11	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
WO2024194455A1 (en)	2023-03-23	2024-09-26	Sanofi	CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8718779D0 (en) *	1987-08-07	1987-09-16	Grosveld F G	Dna sequence & expression vector
US5015570A (en) *	1988-05-13	1991-05-14	Molecular Therapeutics, Inc.	Molecular diagnosis of Alzheimer Disease
EP0451700A1 (en) *	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
WO1994002595A1 (en) *	1992-07-17	1994-02-03	Ribozyme Pharmaceuticals, Inc.	Method and reagent for treatment of animal diseases
US5854392A (en) *	1992-08-31	1998-12-29	Bristol-Myers Squibb Company	β APP-C100 receptor
US5449604A (en) *	1992-10-21	1995-09-12	University Of Washington	Chromosome 14 and familial Alzheimers disease genetic markers and assays
GB9410922D0 (en) *	1994-06-01	1994-07-20	Townsend Alain R M	Vaccines
WO1997012992A2 (en) *	1995-10-02	1997-04-10	Royal Netherlands Academy Of Arts And Sciences	Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore

1998
- 1998-04-02 JP JP54254598A patent/JP2001522241A/ja active Pending
- 1998-04-02 EP EP98917502A patent/EP0971952A2/en not_active Withdrawn
- 1998-04-02 CA CA002287084A patent/CA2287084A1/en not_active Abandoned
- 1998-04-02 WO PCT/IB1998/000705 patent/WO1998045322A2/en not_active Application Discontinuation
- 1998-04-02 AU AU70715/98A patent/AU7071598A/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2001522241A (ja)	2001-11-13
WO1998045322A3 (en)	1999-04-15
EP0971952A2 (en)	2000-01-19
AU7071598A (en)	1998-10-30
WO1998045322A2 (en)	1998-10-15

Publication	Publication Date	Title
CA2287084A1 (en)	1998-10-15	Diagnosis method and reagents
US5958684A (en)	1999-09-28	Diagnosis of neurodegenerative disease
AU691469B2 (en)	1998-05-21	DNA encoding taurine and gaba transporters and uses thereof
US6322976B1 (en)	2001-11-27	Compositions and methods of disease diagnosis and therapy
US6620914B1 (en)	2003-09-16	Transcription factor islet-brain 1 (IB1)
JP2007524583A (ja)	2007-08-30	自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
JP2001518303A (ja)	2001-10-16	スフィンゴシン−１−リン酸リアーゼポリペプチド、ポリヌクレオチド、ならびにそれらについての調節剤および使用方法
US20080085323A1 (en)	2008-04-10	Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders
US7208475B2 (en)	2007-04-24	Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US7183400B1 (en)	2007-02-27	Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes
AU5651899A (en)	2000-04-10	Ly6h gene
US6596500B1 (en)	2003-07-22	Binding of retinoids to M6P/IGF-II receptor
JP2006511194A (ja)	2006-04-06	テネウリンｃ末端関連ペプチド（ｔｃａｐ）並びにこれらに関連する方法および使用
AU767718B2 (en)	2003-11-20	Novel mutations in the (FREAC3) gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis
US7211649B1 (en)	2007-05-01	Cartilage intermediate layer protein
AU732547B2 (en)	2001-04-26	Novel cyclin-selective ubiquitin carrier polypeptides
KR20010030862A (ko)	2001-04-16	프리세닐린과 상호작용할 수 있는 단백질을 암호화하는 핵산
US8138307B2 (en)	2012-03-20	Parkin interacting polypeptides and methods of use
JP2008504270A (ja)	2008-02-14	嚢胞性疾患を処置するための方法および組成物
JP2006525244A (ja)	2006-11-09	糖尿病の治療標的としてのインスリン誘導性遺伝子
WO2022125415A1 (en)	2022-06-16	Scg2 neuropeptides and uses thereof
US6790936B1 (en)	2004-09-14	CAI resistance proteins and uses thereof
WO2006118313A1 (ja)	2006-11-09	新規ポリペプチドおよびその用途
US20030186375A1 (en)	2003-10-02	Nuclear myosin I beta with a 16 amino acid N-terminal extension
MXPA00010172A (en)	2001-09-07	Novel mutations in the freac3

Legal Events

Date	Code	Title	Description
2003-04-02	FZDE	Dead